Respiratory Drugs Market Updates

Skyquest Technology's expert advisors continuously track and analyze the latest developments and updates related to respiratory drugs market. Our team of analysts stay abreast of all the recent news stories shaping the industry including new product launches by major companies, strategic partnerships, M&As, Patent filings and industry and regulatory developments.

Respiratory Drugs Market News

in Respiratory Drugs Market
  • In February 2024, GlaxoSmithKline (GSK) acquired Aiolos Bio, a clinical-stage biopharmaceutical company specializing in respiratory and inflammatory conditions. This acquisition centers on Aiolos's lead candidate, AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody aimed at treating adult asthma patients. The deal enhances GSK's respiratory portfolio by introducing a potentially best-in-class therapy for asthma management.
  • In February 2024, AstraZeneca entered into a collaboration with ArtiQ, a developer of AI-driven software designed to enhance clinical trials. This partnership focuses on utilizing AI tools to optimize lung function testing and improve the efficiency of respiratory clinical trials. By integrating ArtiQ's technology, AstraZeneca aims to streamline trial processes and accelerate the development of respiratory therapies.
  • In April 2024, Teva Pharmaceutical Industries Ltd. and Launch Therapeutics, Inc. announced a clinical collaboration agreement to advance the research program of Teva’s inhaled corticosteroid-short-acting beta agonist (ICS-SABA) combination therapy. This partnership aims to accelerate the clinical development of the ICS-SABA therapy, potentially offering improved treatment options for respiratory conditions.
REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Respiratory Drugs Market size was valued at USD 2.81 Billion in 2023 and is poised to grow from USD 3.03 Billion in 2024 to USD 5.52 Billion by 2032, growing at a CAGR of 7.8% in the forecast period (2025-2032).

The competitive landscape of the global respiratory drugs industry in 2024 is marked by the dominance of major pharmaceutical players alongside emerging startups leveraging innovative technologies. Established companies like GSK, AstraZeneca, Pfizer, and Boehringer Ingelheim continue to lead with their broad portfolios of respiratory treatments, ranging from inhalers and biologics to cutting-edge smart inhalers and combination therapies. These companies are focusing on strategic mergers and acquisitions to enhance their respiratory drug offerings. 'GSK (GlaxoSmithKline)', 'AstraZeneca', 'Pfizer', 'Sanofi', 'Verona Pharma', 'Moderna', 'Lupin Pharmaceuticals', 'Glenmark Pharmaceuticals', 'Viatris', 'Boehringer Ingelheim', 'Novartis', 'Merck & Co.'

AI is revolutionizing how new respiratory drugs are discovered by rapidly analyzing large-scale datasets to identify promising compounds and biological targets. Machine learning algorithms can simulate how drug candidates will interact with human biology, significantly shortening the preclinical phase. For example, AI platforms like BenevolentAI and Atomwise are being utilized to develop novel therapies for asthma and chronic obstructive pulmonary disease (COPD), enabling pharmaceutical firms to innovate faster and reduce R&D expenditures.

Rise of AI-Enabled Smart Inhalers: A growing respiratory drugs market trend in respiratory care is the adoption of AI-integrated smart inhalers that track medication usage, monitor symptoms, and alert users about incorrect techniques or missed doses. Devices like Propeller Health’s inhaler sensors provide real-time feedback to patients and actionable data to clinicians. This not only improves adherence but also helps in tailoring treatment plans based on actual usage and response.

What is Driving the Growth of the Respiratory Drugs Market in North America?

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Respiratory Drugs Market
Respiratory Drugs Market

Report ID: SQMIG35I2377

[email protected]
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE